Still saying Q3 for the data from the 2nd P2 for TRV130, but clinical trials .gov says Jun so hopefully it will be within 1-2 months.
I would suspect late Q3 or Q4 we would hear word on the P3 trial plans for 130 (still saying they hope to start on Q1 '16, but would be nice to hear some more details).
The heart failure drug (027) is looking at Q1 '16 for data. This one has a go-nogo by their partner which could provide a milestone payment.
And that is about it for anything that can actually move the stock.
Only about $10M ( and that is next Q).
But that's a start. Should be at $40M/Q or so by EOY. Add that to cash in hand of about $200M and things are OK by me.